logo
Plus   Neg
Share
Email

Acceleron Pharma's ACE-083 Fails In Phase 2 Study For FSHD

Acceleron Pharma Inc. (XLRN) on Monday said its investigational therapy ACE-083 for the treatment of facioscapulohumeral muscular dystrophy (FSHD) did not achieve functional secondary endpoints in the Phase 2 trial.

Although ACE-083 showed a significant increase in mean total muscle volume, which was the primary endpoint of the trial, the secondary endpoint of functional tests was failed. As a result, the company is not planning to continue with further study of ACE-083 for FSHD.

FSHD is a genetic muscle disorder that starts usually before the age of 20. It first affects the muscles of the face, shoulder blades and upper arms by weakening them, and gradually spreads to other muscles.

ACE-083 is also being explored as a potential treatment for Charcot-Marie-Tooth disease—a neuromuscular disorder, and a phase II trial in this indication is underway. Topline results from this trial are expected in the first quarter of the next year.

XLRN closed Monday's trading at $44.65, up 1.71%. In after-hours, the stock was down 6.83% to $41.60.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Online-video streaming giant Netflix Inc. (NFLX), Tuesday reported a fourth-quarter profit that trounced Wall Street estimates, as revenues surged 31% driven by strong subscriber growth. Netflix added 8.76 million subscribers globally in the quarter, above its forecast of 7.60 million, to end the... Fast food chain Krystal Company has filed for bankruptcy, according to reports. The Atlanta-based Krystal filed for Chapter 11 on Sunday in the U.S. Bankruptcy Court in Atlanta. In the filing, the company reportedly disclosed assets between $10 million and $50 million, and liabilities between $50 million and $100 million. The chief executive officer of Google's parent company Alphabet called for artificial intelligence or AI to be regulated, noting that there are real concerns about the potential negative consequences of the technology. According to Alphabet CEO Sundar Pichai, there are real concerns about the negative consequences of AI, from deepfakes to nefarious uses of facial recognition.
Follow RTT
>